Tier 2 — strong

Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

Yulug B, Altay O, Li X, Hanoglu L, Cankaya S, Lam S, Velioglu HA, Yang H, Coskun E, Idil E, Nogaylar R, Ozsimsek A, Bayram C, Bolat I, Oner S, Tozlu OO, Arslan ME, Hacimuftuoglu A, Yildirim S, Arif M, Shoaie S, Zhang C, Nielsen J, Turkez H, Borén J, Uhlén M, Mardinoglu A
Translational neurodegeneration 2023 12; 1; 4

Bibliography

PubMed
PMID 36703196
PubMed Central
PMC9879258
DOI
10.1186/s40035-023-00336-2
Funding
Knut and Alice Wallenberg Foundation, EU research support and institutional resources; ChromaDex supplied NR.
Competing interests
Three authors were founders and shareholders of ScandiBio Therapeutics.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample69 assigned; 60 completed day 84
InterventionPer dose: NR 1 g, serine 12.35 g, NAC 2.55 g and carnitine tartrate 3.73 g
Duration84 days; once daily initially, then twice daily
EndpointsCognitive scores; daily function; metabolic profiles

What the study showed, in plain terms

The combination study reported cognitive-score and metabolic signals, particularly in participants with higher baseline impairment.

Key findings

The combination study reported cognitive-score and metabolic signals, particularly in participants with higher baseline impairment.

What this study can and cannot tell us

Four active ingredients, subgroup emphasis and exploratory molecular analyses preclude attributing cognitive benefit to NR alone.

Related papers in the corpus

Tier 2
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial
Yulug B et al. · Brain communications · 2025
Tier 2
The acute effect of different NAD + precursors included in the combined metabolic activators
Li X et al. · Free radical biology & medicine · 2023
Tier 2
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
Altay O et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
Tier 2
Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients
Zeybel M et al. · Molecular systems biology · 2021

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology